X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
LB-P8 is an investigational live biotherapeutic product consisting of a single bacterial strain (Leuconostoc citreum). It is being evaluated for the treatment of primary sclerosing cholangitis.
Lead Product(s): LB-P8
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: LB-P8
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 29, 2024
Details:
LB-P8 is an investigational live biotherapeutic product consisting of a single bacterial strain (Leuconostoc citreum). It is being evaluated for the treatment of primary sclerosing cholangitis.
Lead Product(s): LB-P8
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: LB-P8
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 29, 2024
Details:
Under the agreement, Celltrion and LISCure intend to develop, oral LBPs, microbiome-based therapies, for Parkinson's disease. LISCure advances brain-target bacterial exosome technology for neurodegenerative diseases based on its platform technology.
Lead Product(s): Microbiome-based Therapy
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Large molecule
Partner/Sponsor/Collaborator: Celltrion
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration February 20, 2023
Details:
LB-P8, LISCure's microbiome novel drug, as treatment of PSC. LB-P8 is, to the best of company's knowledge, the first drug to be granted orphan drug designation in the field of microbiome-based treatment for metabolic diseases.
Lead Product(s): LB-P8
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: LB-P8
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 08, 2022
Details:
LB-P6 and LB-P8, targeting autoimmune disease and non-alcoholic steatohepatitis (NASH), respectively. LB-P6 is a candidate substance that is expected to have therapeutic effects on various autoimmune diseases.
Lead Product(s): LB-P8
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: LB-P8
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 28, 2022
Details:
LB-P6 and LB-P8, targeting autoimmune disease and non-alcoholic steatohepatitis (NASH), respectively. LB-P6 is a candidate substance that is expected to have therapeutic effects on various autoimmune diseases.
Lead Product(s): LB-P8
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: LB-P8
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 30, 2021
Details:
LISCure Biosciences will receive Mayo Clinic's know-how to establish a new drug, LB-P8, development of NASH program. As part of the agreement, Mayo Clinic will become a shareholder in LISCure, the first Korean biotech company receiving equity investment from Mayo Clinic.
Lead Product(s): LB-P8
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: LB-P8
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Mayo Clinic
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement July 27, 2021
Details:
LISCure is developing the world's first microbiome-based NASH(non-alcoholic steatohepatitis) treatment, LB-P8, as well as the rheumatoid arthritis treatment, LB-P6, for global clinical trials.
Lead Product(s): LB-P8
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: LB-P8
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $21.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing February 26, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
